During the last three months, 11 analysts shared their evaluations of Centene CNC, revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 7 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 2 | 1 | 0 | 0 |
| 3M Ago | 0 | 3 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Centene, presenting an average target of $92.64, a high estimate of $110.00, and a low estimate of $82.00. This current average represents a 1.91% decrease from the previous average price target of $94.44.
Diving into Analyst Ratings: An In-Depth Exploration
A clear picture of Centene's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Wiederhorn | Oppenheimer | Maintains | Outperform | $110.00 | $110.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $90.00 | $90.00 |
| Scott Fidel | Stephens & Co. | Maintains | Equal-Weight | $83.00 | $83.00 |
| Michael Ha | Baird | Announces | Neutral | $83.00 | - |
| Andrew Mok | Barclays | Raises | Overweight | $104.00 | $101.00 |
| George Hill | Deutsche Bank | Raises | Hold | $82.00 | $81.00 |
| Michael Wiederhorn | Oppenheimer | Maintains | Outperform | $110.00 | $110.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $93.00 | $89.00 |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $89.00 | $94.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $90.00 | - |
| Scott Fidel | Stephens & Co. | Lowers | Equal-Weight | $85.00 | $92.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Centene. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Centene compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Centene's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Centene's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Centene analyst ratings.
Unveiling the Story Behind Centene
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Understanding the Numbers: Centene's Finances
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Centene's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.9% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.88%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 4.41%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.39%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.67, caution is advised due to increased financial risk.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
